| You are here: Home: BCU 9|2003: Stephen E Jones, MD: Select publications
Select publications
Publications discussed by Dr Jones
Bear HD et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003;21(22):4165-74. Abstract
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract
Heys SD et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;(3 Suppl 2):69-74. Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20(16):3396-403. Abstract
Jones S et al. Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Breast Can Res Treat 2003; 82(Suppl 1):9;Abstract 10.
Jones SE et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/ cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc ASCO 2003;Abstract 59.
Mamounas EP et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc ASCO 2003;Abstract12 .
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node-positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc ASCO 2002; Abstract 141.
Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
O'Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Perey L et al. Fulvestrant ('Faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Can Res Treat 2002;76 (Suppl 1):72;Abstract 249.
Ravdin P et al. Phase III comparison of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC). Eur J Cancer Suppl 2003;1(5):201;Abstract 670.
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Steger GG et al. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc ASCO 2003;Abstract 78.
Vergote I et al; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79(2):207-11. Abstract
Watanabe T et al. Fulvestrant provides clinical benefit to postmenopausal women with metastatic breast cancer who have relapsed on prior antiestrogen therapy: A Japanese study. Proc ASCO 2003;Abstract 274.
|
